Sudeep Pharma Q2 FY27 Results: Key Dates and Q1 Growth

Board meeting set for October 28

Sudeep Pharma Ltd is scheduled to consider its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company’s board meeting is scheduled for Wednesday, October 28, 2026. This update places the focus on the company’s Q2 and H1 FY27 financial performance. The results will follow a June quarter in which the company reported year-on-year growth in sales and profit. Sudeep Pharma manufactures excipients and specialty ingredients for pharmaceutical, food and nutrition industries in India, the US and other international markets.

Earnings call planned for October 29

The company has scheduled an earnings call for October 29, 2026, at 12:00 noon IST. Management is expected to discuss Q2 and H1 FY27 operational and financial performance on the call. Analysts and investors have been invited through a registration link and dial-in details announced by the company. A separate announcement said Sudeep Pharma would report Q2 2027 results on October 29. The October 28 board meeting and October 29 investor call therefore form the immediate events investors will track.

June-quarter revenue rose 26.7%

For the quarter ended June 2026, Sudeep Pharma reported consolidated sales of ₹158.27 crore, compared with ₹124.92 crore in the corresponding quarter a year earlier. That represented year-on-year sales growth of 26.70%. The company also described June-quarter revenue as approximately ₹158 crore in its earnings information. On a sequential basis, revenue was down 13.20% from the preceding quarter. The comparison reflects sales of ₹182.34 crore reported for the March 2026 quarter.

Net profit increased over the prior year

Consolidated net profit for the June 2026 quarter rose 31.61% year-on-year to ₹40.55 crore from ₹30.81 crore in June 2025. Other reported June-quarter data placed profit at approximately ₹41.0 crore, with year-on-year growth of 32.3%. Sequentially, net profit declined 16.38% from ₹48.88 crore in the March 2026 quarter. The June-quarter earnings per share was reported at ₹3.59, against ₹3.17 a year earlier. This represented growth of 13.2% in earnings per share.

Gross profit and operating margin data

Gross profit for the June 2026 quarter was reported at ₹50 crore. It increased 25.33% from the year-earlier period but declined 13.29% sequentially. Sudeep Pharma reported EBITDA of ₹54.9 crore for Q1 FY27, up 25% year-on-year. EBITDA margin was reported at 34.7%. Operating margin was separately reported at 35.0%, unchanged from the June 2025 quarter.

Key reported financial figures

Full-year FY26 performance provides context

For the year ended March 2026, Sudeep Pharma reported sales of ₹642.26 crore, up 27.94% from ₹502.00 crore in the previous year. Full-year net profit rose 24.62% to ₹172.89 crore from ₹138.73 crore. In the March 2026 quarter, sales increased 15.73% year-on-year to ₹182.34 crore. Net profit for that quarter rose 10.61% to ₹48.88 crore. These reported figures provide the financial backdrop for the upcoming half-year update.

Nandesari facility has received FDA approval

Sudeep Pharma has announced FDA approval for its new greenfield manufacturing facility at 179 Nandesari in Gujarat. The approval enables commencement of operations at the site. The facility adds annual capacity of 51,200 MT for pharmaceutical, food, nutrition and specialty ingredients. The company has said commercial supplies are expected to begin in H2 FY27 after customer qualification processes are completed. The timing of qualification and supply commencement remains relevant to the company’s operating updates.

Trading window remains closed

The company’s insider trading window has been closed from October 1 to October 30, 2026. The closure covers the period around consideration of the quarterly and half-yearly financial results. Such trading-window restrictions are commonly applied during periods when unpublished price-sensitive information may be available. Sudeep Pharma’s disclosed closing date is October 30, 2026. Investors will await the board’s result announcement and management commentary on October 29.

What investors will monitor

The scheduled result update will provide the first reported financial view of the July-September 2026 quarter. Key disclosed reference points include June-quarter revenue of ₹158.27 crore, net profit of ₹40.55 crore and EBITDA of ₹54.9 crore. Investors may also look for management updates on the Nandesari facility, customer qualification and expected commercial supplies in H2 FY27. The company has not provided Q2 FY27 financial numbers in the available information. The next confirmed events are the October 28 board meeting and October 29 earnings call.